We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RELX:NYSERELX PLC PLC Analysis

Data as of 2026-05-24 - not real-time

$33.01

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

RELX trades at $33.01, sitting just above the computed support level of $31.02 and below both the 20‑day (≈$34.31) and 50‑day (≈$34.27) simple moving averages, indicating limited short‑term upside. The RSI of 42 and a bearish MACD histogram reinforce a neutral‑to‑slightly bearish technical backdrop, with the price also facing resistance near $36.90. Fundamentally, the company posts a solid operating margin of 31% and a striking ROE of 70%, but its balance sheet is heavily leveraged (debt‑to‑equity ≈304) and cash reserves are modest relative to debt. The forward PE of 15.2 and a current PE of 21.9 are well below the industry average of 29.7, suggesting a relative value edge, yet the DCF‑derived fair value of $12.70 is far beneath the market price, highlighting a potential overvaluation signal. Dividend sustainability appears reasonable with a 2.79% yield and a 57% payout ratio supported by strong operating cash flow. Overall, the stock sits in a low‑beta (≈0.48) environment with 30% 30‑day volatility, offering modest defensive characteristics but heightened financial risk due to leverage. The confluence of bearish technical cues, strong margins, high debt, and divergent valuation signals suggests a cautious stance, especially for longer horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMAs and near support
  • Bearish MACD and neutral RSI
  • Stable volume with limited upside to resistance

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong operating margins and ROE
  • High debt‑to‑equity ratio limiting financial flexibility
  • Valuation gap between market price and DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Overvaluation relative to intrinsic DCF estimate
  • Elevated leverage and modest cash cushion
  • Technical indicators pointing to continued downside pressure

Key Metrics & Analysis

Financial Health

Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio21.9
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio76.3
Op. Cash Flow$2.8B
Free Cash Flow$2.2B
Industry P/E29.7

Technical Analysis

TrendNeutral
RSI42.1
Support$31.02
Resistance$36.90
MA 20$34.31
MA 50$34.27
MA 200$39.76
MACDBearish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair Value$12.70
Target Price$52.45
Upside/Downside58.89%
GradeOvervalued
TypeValue
Dividend Yield2.79%

Risk Assessment

Beta0.48
Volatility30.90%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.